Novavax (NVAX) closed at $8.76 on November 12, 2026, down 12.2% from the previous close, on volume of 6,654,402 shares (30-day average 7,784,590).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | 5 Leg Call/Put Combo Calendar with Ratio | Bunched | 4,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Novavax to Participate in Jefferies London Healthcare Conference
PRNewswire (Wed, 11-Nov 5:00 PM ET)
Novavax points to a $125 million Sanofi milestone as Q3 expense cuts narrow losses
Market Chameleon (Thu, 5-Nov 4:05 AM ET)
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
PRNewswire (Thu, 5-Nov 8:00 AM ET)
Market Chameleon (Fri, 30-Oct 3:37 AM ET)
PRNewswire (Thu, 29-Oct 9:38 AM ET)
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire (Thu, 29-Oct 8:00 AM ET)
Novavax to Participate in September Investor Conferences
PRNewswire (Wed, 2-Sep 5:00 PM ET)
PRNewswire (Fri, 28-Aug 8:30 AM ET)
Novavax’s Matrix-M Partnerships Expand to Over 30 Therapeutic Targets Amid Revenue Shift
Market Chameleon (Thu, 7-May 4:20 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of November 13, 2026, NVAX stock price declined to $8.57 with 1,307,492 million shares trading.
NVAX has a beta of 2.29, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.18 to the broad based SPY ETF.
NVAX has a market cap of $1.41 billion. This is considered a Small Cap stock.
Last quarter Novavax reported $68 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.16.
In the last 3 years, NVAX traded as high as $23.86 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): VTI, XBI, VB, IWM, VBK.
NVAX has outperformed the market in the last year with a return of +19.0%, while the SPY ETF gained +10.8%. In the last 3 month period, NVAX beat the market returning +7.7%, while SPY returned -2.7%. However, in the most recent 2 weeks NVAX has underperformed the stock market by returning -18.1%, while SPY returned -2.5%.
NVAX support price is $8.28 and resistance is $9.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.
